• SPX
  • $5,766.36
  • 0.94 %
  • $53.67
  • DJI
  • $42,097.33
  • 0.72 %
  • $302.73
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,175.26
  • -0.11 %
  • -$8.98
  • IXIC
  • $18,394.80
  • 1.18 %
  • $214.81
Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Price, News & Analysis

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Price, News & Analysis

Currency in USD Disclaimer

$21.92

$0.44

(2.05%)

Day's range
$20.66
Day's range
$21.97
50-day range
$20.26
Day's range
$28.15
  • Country: BM
  • ISIN: BMG5269C1010
52 wk range
$14.12
Day's range
$28.15


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 7.58
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (KNSA)
  • Company Kiniksa Pharmaceuticals, Ltd.
  • Price $21.92
  • Changes Percentage (2.05%)
  • Change $0.44
  • Day Low $20.66
  • Day High $21.97
  • Year High $28.15

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $35.00
  • High Stock Price Target $40.00
  • Low Stock Price Target $34.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.13
  • Trailing P/E Ratio 146.62
  • Forward P/E Ratio 146.62
  • P/E Growth 146.62
  • Net Income $14.08 M

Income Statement

Quarterly

Annual

Latest News of KNSA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.